FinancialBuzz.com News Commentary
Cannabis has been used for medicinal purposes for centuries, but despite the therapeutic benefits of cannabis, international regulators ultimately deemed the plant unsafe for the public due to its marijuana derivative. The marijuana plant, which is part of the cannabis family, is linked to containing the majority of THC cannabinoids, which cause the psychoactive effects that cannabis is generally associated with. However, extensive research and studies have uncovered that marijuana can be effectively used to treat a variety of medical conditions. For instance, researchers suggested that marijuana can effectively be used as an alternative to traditional opioids to treat moderate to severe pain. A study published in the Journal of Psychoactive Drugs evaluated over 1,000 subjects taking legal marijuana. Among the participants, 65% of the people said they were taking cannabis for pain treatment and 80% of the group found it very or extremely helpful. As a result, this led to 82% of the group reducing or eliminating their over the counter (OTC) medication intake. Notably, 88% of the group mentioned that they were able to completely stop taking opioid painkillers. Furthermore, 74% of the subjects said that marijuana helped them sleep better. Chronic pain and insomnia are two of the most prevalent medical conditions that adults suffer from and Dr. Gwen Wurm, Assistant Professor of Clinical Pediatrics at the University of Miami Miller School of Medicine, highlighted that 20% of American adults suffer from chronic pain and one in three do not get enough sleep in general. However, in regions where marijuana is legal for medical treatment, patients can obtain a prescription from their doctor to treat their ailments. Furthermore, as research and studies continue to better develop our collective understanding of the plant, scientists are debunking the misconceptions revolving around marijuana. This, in turn, is driving the large influx of first time users. According to data compiled by Zion Market Research, the global legal marijuana market was valued at USD 16.71 Billion in 2017. By 2024, the market is projected to reach USD 62.96 Billion, registering a CAGR of 21% during the forecasted period between 2018 and 2024. Canopy Rivers Inc. (OTC: CNPOF) (TSX-V: RIV), TerrAscend Corp. (OTC: TRSSF) (CSE: TER), Aphria Inc. (NYSE: APHA) (TSX: APHA), Cresco Labs Inc. (OTC: CRLBF) (CSE: CL), Origin House (OTC: ORHOF) (CSE: OH).
Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (TSXV: RIV) (OTC: CNPOF) congratulates its portfolio company TerrAscend Corp. (“TerrAscend”) (CSE: TER) (OTCQX: TRSSF) on its announcement today that it has received an amendment to its licence from Health Canada allowing for the sale of cannabis oils from its facility in Mississauga, Ontario. Sales of TerrAscend’s cannabis oils are set to begin immediately through its medical marketplace, Solace Health. This news comes two months following TerrAscend’s announcement that it had been issued a Good Manufacturing Practice (GMP) certificate in accordance with the rules governing medical products in the European Union, in conjunction with establishing a sales and distribution agreement with iuvo Therapeutics GmbH, a German pharmaceutical wholesaler.
Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (TSXV: RIV) (OTC: CNPOF) congratulates its portfolio company TerrAscend Corp. (“TerrAscend”) (CSE: TER) (OTCQX: TRSSF) on its announcement yesterday that its facility in Mississauga, Ontario, Canada has been issued a Good Manufacturing Practice (“GMP”) certificate in accordance with the rules governing medicinal products in the European Union (“EU”). TerrAscend also entered into a comprehensive sales and distribution agreement with iuvo Therapeutics GmbH (“iuvo”), a German pharmaceutical wholesaler.
FinancialBuzz.com News Commentary
CORAL GABLES, FL / ACCESSWIRE / January 22, 2019 / The market around the nation has become extremely positive in the past year and beyond. With so many changes happening around the market, whether it be legislative or other, market analysts have stated that this could be the year of cannabis. With the market predicted to reach $55.0 billion by 2024, according to a new research study published by Global Market Insights, Inc, it stands to reason that companies with the ability to combine the complex medical applications of cannabis with integrative healthcare frameworks could create potential opportunities from entering the nascent marijuana industry. With the new year onlyone month old, , Cronos Group Inc (NASDAQ: CRON) (TSX: CRON), TerrAscend Corp (OTCQX: TRSSF), and GW Pharmaceuticals plc (NASDAQ: GWPH) are four pot stocks representing companies helping the whole of their industry move forward.
Financialnewsmedia.com News Commentary
Despite the bear market that has been upon us in recent days, marijuana companies haven’t shown weakness and have remained at a relatively strong stock price levels. Below are five companies in this growing industry worth researching, but first some data on the industry. According to a report published by Hexa Research, the U.S. medical cannabis market is expected to grow significantly to reach USD 19.48 Billion by 2024. Increasing signs of medical benefits received from the use of cannabis has been one of the key drivers to fuel the U.S. medical market. Additionally, the number of states legalizing cannabis for medical consumption continues to increase due to its greater consumer acceptance as well as the increasing number of companies entering the market. Cannabis infused products are expected to gain popularity in the U.S. as the cannabis-infused solid-edibles segment dominated the U.S market in 2016 and is expected to grow at a compound annual growth rate (CAGR) of 17.8% over the forecast period. CLS Holdings USA Inc. (OTC: CLSH) TerrAscend Corp. (OTC: TRSSF), MariMed Inc. (OTC: MRMD), Cannabis Sativa, Inc. (OTC: CBDS), The Supreme Cannabis Company (OTC: SPRWF)
According to a report published by Coherent Market Insights, the global medical cannabis market was valued at USD 3.5 Billion in 2017 and is projected to grow at a compound annual growth rate (CAGR) of 24.4% to surpass USD 20.17 Billion by 2025. The report indicated that the increasing clinical trials and approvals of medical cannabis products will drive the growth of the market. Medical cannabis is used to develop drugs that will enhance the treatment for diseases such as epilepsy and various types of cancers. Additionally, the growing acceptance of the mobile application, e-commerce and digital media is projected to fuel the growth of the medical cannabis market during forecast years. MariCann Group Inc. (OTC: MRRCF), MariMed Inc. (OTC: MRMD), TerrAscend Corp. (OTC: TRSSF), Leafbuyer Technologies, Inc. (OTC: LBUY), Emblem Corp. (OTC: EMMBF)